Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VVT MedVVTMF EV-to-EBITDA is -3.66 as of Jul. 30, 2026. The stock has 5 warning signs investors should review. Among 510 Medical Devices & Instruments companies, VVT Med ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, VVT Med's enterprise value is $12.88 Mil.
VVT Med's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.52 Mil. Therefore, VVT Med's EV-to-EBITDA for today is -3.66.
The historical rank and industry rank for VVT Med's EV-to-EBITDA or its related term are showing as below:
VVTMF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.47 Med: -4.29 Max: -2.77
Current: -3.75
During the past 4 years, the highest EV-to-EBITDA of VVT Med was -2.77. The lowest was -35.47. And the median was -4.29.
VVTMF's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.265
vs VVTMF: -3.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-30), VVT Med's stock price is $0.1568.
VVT Med's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.060. Therefore, VVT Med's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
VVT Med (OTCPK:VVTMF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VVT Med's share price for today is $0.1568.
VVT Med's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for VVT Med's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, VVT Med's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VVT Med EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VVT Med's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where VVT Med's EV-to-EBITDA falls into.
VVT Med's current Enterprise Value is $12.88 Mil.
VVT Med's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VVT Med (VVTMF) has a EV-to-EBITDA of -3.66 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on VVT Med. According to the industry distribution chart, VVT Med ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is VVT Med's EV-to-EBITDA too high?
VVT Med's current EV-to-EBITDA is -3.66. Based on the distribution chart, VVT Med ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does VVT Med's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VVT Med ranks #999999 out of 510 companies for EV-to-EBITDA. This places VVT Med in the lower half of its industry. The industry median EV-to-EBITDA is 14.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.27, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on VVT Med. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VVT Med's current EV-to-EBITDA is -3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VVT Med stock overvalued right now?
VVT Med (VVTMF) has a current EV-to-EBITDA of -3.66. The current EV-to-EBITDA is -3.66. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For VVT Med (VVTMF), the current EV-to-EBITDA is -3.66 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VVT Med Inc is a medical device company, focused on developing and commercializing a range of minimally invasive technologies for treating varicose veins. VVT's research and development activities are based in Israel. The company proudly boasts three products within its portfolio that have achieved commercial production status and are currently available in the market. These products have undergone meticulous design processes, obtaining regulatory approvals across multiple countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVTMF has been successfully added to your 
